Salivary gland cancers are a rare, histologically diverse group of tumors. They range from
indolent to aggressive and can cause significant morbidity and mortality. Surgical resection …

Salivary gland carcinomas (SGC) account for less than 5% of head and neck malignant
neoplasms, further subcategorized in over 20 histological subtypes. For the most part …

Purpose Clinical evidence demonstrating the effectiveness of systemic therapy for advanced
salivary duct carcinoma (SDC) is lacking because of the disease's rarity. We assessed the …

Salivary duct carcinoma (SDC) is an aggressive subtype of primary salivary gland
carcinoma, often with an advanced stage at presentation and high rates of metastasis and …

Background HER2 aberrations in salivary gland carcinomas (SGC) as well as benefit of
HER2 directed therapy have been reported in small studies. However, reliable estimates of …

Background: The efficacy and safety of human epidermal growth factor receptor 2 (HER2)-
targeted therapy and androgen deprivation therapy (ADT) for locally advanced or recurrent …

Salivary duct carcinoma (SDC) is aggressive with limited therapeutic options. A subset of
SDC display human epidermal growth factor receptor 2 (HER2) protein overexpression by …

Salivary gland cancers (SGCs), categorized as head and neck cancers (HNCs), constitute
about 6% of head and neck cancer diagnoses based on estimate by American Head and …

Rationale: Treatment options for recurrent and/or metastatic (R/M) adenoid cystic carcinoma
(ACC) and salivary duct carcinoma (SDC), major subtypes of salivary gland cancer, are …

Background Distant metastases (DMs) are the primary cause of treatment failure in patients
with salivary gland carcinoma. There is no consensus on the standard treatment. Methods …